FUTURE DIAGNOSTICS SOLUTIONS BV

Their core work

Future Diagnostics Solutions is a Dutch SME specializing in advanced optical and photonic diagnostic technologies for cancer detection and treatment monitoring. Their work centers on developing miniaturized, highly sensitive diagnostic platforms that use light-based sensing — plasmonic and bio-photonic methods — to detect cancer biomarkers at very early stages. They operate at the intersection of medical diagnostics, photonics engineering, and clinical decision support, contributing device-level expertise to research consortia. Their commercial positioning appears to be translating research-grade optical sensing into practical diagnostic tools for oncology applications.

What they specialise in

How they've shifted over time

Both projects fall within a relatively narrow 2015–2020 window, so there is no long multi-decade arc to trace. However, there is a meaningful shift in focus even across just two projects: their first project (ULTRAPLACAD) concentrated on upstream detection — catching cancer early using plasmonic sensor sensitivity. Their second project (BIOCDx) moved downstream into companion diagnostics — supporting treatment decisions once cancer is already diagnosed. This reflects a maturation from pure detection technology toward integrated clinical utility, and the sector classification shift from Health to Digital signals increasing emphasis on the data processing and software layers of diagnostics, not just the optical hardware.

They are moving from pure detection hardware toward integrated clinical decision tools, suggesting future collaborations with them would benefit from combining photonic sensing with digital health, biomarker data analysis, or regulatory/clinical validation expertise.

How they like to work

Future Diagnostics Solutions has participated exclusively as a consortium partner, never as a project coordinator, across both H2020 projects — indicating they prefer contributing specialist expertise rather than leading project management. Despite only two projects, they engaged with 25 distinct partners across 10 countries, which is a notably broad network for such a small portfolio, suggesting they join large multi-partner RIA consortia rather than tight bilateral collaborations. This profile is typical of a technology SME that brings a specific proprietary device or platform capability that larger consortia need but cannot develop in-house.

With 25 unique partners across 10 countries from just two projects, their per-project network density is high, reflecting participation in large research consortia typical of EU health and photonics RIAs. Their geographic spread across 10 countries suggests European-scale integration but no identified focus on any single region.

What sets them apart

Future Diagnostics Solutions occupies a specific niche that few SMEs cover: the translation of advanced optical physics (plasmonics, bio-photonics) into practical oncology diagnostic devices. While larger medical device companies focus on established detection methods (ELISA, PCR), this company brings expertise in next-generation photonic sensing that can detect cancer markers at lower concentrations and in smaller form factors. For a consortium building a cancer diagnostics project, they offer device-level prototyping and optical sensing expertise that academic partners typically cannot provide and that industrial giants may not prioritize at early TRL stages.

Highlights from their portfolio

• ULTRAPLACAD
  Their largest funded project (€524,375) and earliest H2020 entry, focused on plasmonic sensor development for early-stage cancer diagnosis — a high-impact clinical problem with broad applicability across tumor types.
• BIOCDx
  Demonstrates a strategic pivot toward companion diagnostics, a commercially significant and growing segment where diagnostic results directly guide treatment selection, bridging photonics and clinical oncology decision-making.